Novozymes South Asia Profile
Key Indicators
- Authorised Capital ₹ 110.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 106.00 Cr
as on 16-11-2024
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 14.15%
(FY 2023)
- Profit 26.51%
(FY 2023)
- Ebitda 14.11%
(FY 2023)
- Net Worth 11.21%
(FY 2023)
- Total Assets 6.63%
(FY 2023)
About Novozymes South Asia
The Corporate was formerly known as Novo Nordisk Enzymes Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 110.00 Cr and a paid-up capital of Rs 106.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Novozymes South Asia Private Limited India is Sumedha Hegde as COMPANY SECRETARY. Mikkel Viltoft, Manish Mittal, and Krishnamohan Puvvada serve as directors at the Company.
- CIN/LLPIN
U24299KA1998PTC024038
- Company No.
024038
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Novozymes South Asia Private Limited offer?
Novozymes South Asia Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Toilet Cleaners, Cookware and Cooking Utensils, Cooking Range, PVC, CPVC, HDPE Water Pipe Fittings, Plastic Pipe Fittings, Cleaning Chemicals, Water Treatment & Purification Plant, Sewage Treatment Plants, Extraction Plants and Extruders.
Who are the key members and board of directors at Novozymes South Asia?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumedha Hegde  | Company Secretary | 03-Apr-2018 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manish Mittal | Whole-Time Director | 01-Aug-2016 | Current |
Mikkel Viltoft  | Director | 09-Sep-2009 | Current |
| Krishnamohan Puvvada | Whole-Time Director | 26-Aug-2019 | Current |
Financial Performance and Corporate Structure Insights of Novozymes South Asia.
Novozymes South Asia Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.15% increase. The company also saw a substantial improvement in profitability, with a 26.51% increase in profit. The company's net worth Soared by an impressive increase of 11.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novozymes South Asia?
In 2023, Novozymes South Asia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uas Life Sciences India Private LimitedActive 10 years 9 monthsKrishnamohan Puvvada is a mutual person
Synergia Life Sciences Private LimitedActive 20 years 8 monthsManish Mittal and Krishnamohan Puvvada are mutual person
Riata Life Sciences Private LimitedActive 11 years 11 monthsManish Mittal and Krishnamohan Puvvada are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novozymes South Asia?
Novozymes South Asia has a workforce of 542 employees as of Oct 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novozymes South Asia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novozymes South Asia's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
